BMY Bristol-Myers Squibb Company Stock Quote

BMY [NYSE]

Healthcare | Drug Manufacturers - General | USA

Index	S&P 500	P/E	-	EPS (ttm)	-2.78	Insider Own	0.10%	Shs Outstand	2.24B	Perf Week	0.68%
Market Cap	145.22B	Forward P/E	8.13	EPS next Y	7.99	Insider Trans	-6.93%	Shs Float	2.23B	Perf Month	0.68%
Income	-6219.00M	PEG	-	EPS next Q	1.92	Inst Own	77.00%	Short Float	0.94%	Perf Quarter	8.15%
Sales	42.81B	P/S	3.39	EPS this Y	-298.80%	Inst Trans	0.48%	Short Ratio	1.77	Perf Half Y	2.30%
Book/sh	16.82	P/B	3.86	EPS next Y	7.53%	ROA	-5.10%	Target Price	75.44	Perf Year	1.74%
Cash/sh	5.78	P/C	11.23	EPS next 5Y	7.80%	ROE	-14.20%	52W Range	54.07 - 67.16	Perf YTD	4.59%
Dividend	1.96	P/FCF	16.00	EPS past 5Y	-44.40%	ROI	-12.10%	52W High	-3.39%	Beta	0.60
Dividend %	3.02%	Quick Ratio	1.50	Sales past 5Y	20.80%	Gross Margin	76.70%	52W Low	19.99%	ATR	0.96
Employees	30250	Current Ratio	1.60	Sales Q/Q	2.70%	Oper. Margin	-18.10%	RSI (14)	54.88	Volatility	1.28% 1.52%
Optionable	Yes	Debt/Eq	1.23	EPS Q/Q	360.00%	Profit Margin	-14.50%	Rel Volume	0.63	Prev Close	65.04
Shortable	Yes	LT Debt/Eq	1.18	Earnings	Apr 29 BMO	Payout	-	Avg Volume	11.85M	Price	64.88
Recom	1.90	SMA20	-0.07%	SMA50	2.45%	SMA200	4.75%	Volume	7,555,502	Change	-0.25%

Apr-30-21

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$70 → $62

Apr-13-21

Upgrade

Truist

Hold → Buy

Nov-16-20

Upgrade

Societe Generale

Hold → Buy

$76

Nov-10-20

Resumed

Bernstein

Mkt Perform

Nov-06-20

Downgrade

Gabelli & Co

Buy → Hold

Oct-19-20

Upgrade

Guggenheim

Neutral → Buy

$70

Sep-29-20

Initiated

Berenberg

Buy

$73

Jul-28-20

Initiated

Raymond James

Outperform

$75

Apr-02-20

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$64

Mar-23-20

Downgrade

Societe Generale

Buy → Hold

$50

Feb-27-20

Initiated

Barclays

Equal Weight

$69

Jan-06-20

Resumed

Citigroup

Buy

$73

Dec-13-19

Upgrade

Argus

Hold → Buy

$80

Nov-22-19

Resumed

Morgan Stanley

Equal-Weight

$60

Oct-17-19

Resumed

BofA/Merrill

Buy

$60

Aug-14-19

Upgrade

Atlantic Equities

Neutral → Overweight

$63

May-28-19

Initiated

Goldman

Buy

May-20-19

Downgrade

Argus

Buy → Hold

May-03-19

Upgrade

Barclays

Equal Weight → Overweight

$53 → $55

May-03-19

Resumed

JP Morgan

Overweight

$62

May-16-21 05:51AM	4 Surefire Value Stocks to Buy for a Biden Bull Market Motley Fool
May-15-21 12:15PM	Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Demonstrating Health Status Benefits of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy at American College of Cardiologys 70th Annual Scientific Session Business Wire
09:48AM	The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off Benzinga
May-14-21 03:49PM	ARK Investment's Top 5 New Buys in the 1st Quarter GuruFocus.com
07:15AM	Is BMY Stock A Sell After Panel Recommends FDA Revoke An Opdivo Approval? Investor's Business Daily
06:03AM	2 Top Healthcare Stocks for 2021 and Beyond Motley Fool
May-12-21 04:10PM	Bristol-Myers Squibb: An Uncertain Future GuruFocus.com
11:43AM	Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders Business Wire
May-10-21 05:50PM	Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know Zacks
May-06-21 08:31AM	DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative PR Newswire
08:03AM	DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative PR Newswire
07:15AM	Is BMY Stock A Sell After Panel Recommends FDA Revoke An Opdivo Approval? Investor's Business Daily
May-05-21 06:59AM	Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference Business Wire
May-04-21 06:48AM	2 Top Stocks to Buy and Hold for 10 Years Motley Fool
May-03-21 09:24AM	How Shareholders Missed Out on a Potential $6 Billion in Bristol Myers Deal for Celgene Barrons.com
09:11AM	Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiologys 70th Annual Scientific Session Business Wire
May-02-21 08:30AM	This Data Could Accelerate Bristol Myers Squibb's Cancer Drug Opportunity Motley Fool
May-01-21 11:15AM	What Investors Need to Know About This $419,500 CAR-T Cancer Treatment Motley Fool
Apr-30-21 12:37PM	Bristol Myers Squibbs 1Q Results Miss Estimates; Street Says Buy SmarterAnalyst
06:59AM	U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibbs Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma Business Wire
01:01AM	Bristol-Myers Squibb (BMY) Q1 2021 Earnings Call Transcript Motley Fool
Apr-29-21 04:03PM	Bristol Myers Disappoints In First Quarter, But Retains Its Full-Year Guidance Investor's Business Daily
03:22PM	Why Bristol Myers Squibb Stock Fell Today Motley Fool
10:49AM	Bristol-Myers Misses Q1 Profit As Pandemic Hits Cancer Drugs Sales Benzinga
10:16AM	What Went Wrong for Bristol Myers Squibb in Q1 Motley Fool
09:29AM	Bristol-Myers (BMY) Misses on Q1 Earnings, Opdivo Sales Decline Zacks
09:04AM	Bristol Myers Squibb Stock Fell After Earnings. Heres Why. Barrons.com
08:25AM	Bristol Myers Squibb (BMY) Q1 Earnings and Revenues Miss Estimates Zacks
07:11AM	Bristol Myers Squibb stock falls, as profit and revenue rise but miss expectations MarketWatch
07:01AM	Bristol Myers first-quarter earnings miss expectations as cancer drugs underperform Reuters
06:59AM	Bristol Myers Squibb Reports First Quarter Financial Results for 2021 Business Wire
06:45AM	Bristol Myers Squibb Co. to Host Earnings Call ACCESSWIRE
03:08AM	Bristol Myers Misses Earnings Forecast, Repeats 2021 Profit Guidance TheStreet.com
Apr-28-21 12:45PM	Here is Why Growth Investors Should Buy Bristol Myers (BMY) Now Zacks
11:14AM	Pharma/Biotech Stocks' Q1 Earnings Queued for Apr 29: MRK, BMY & More Zacks
06:59AM	Bristol Myers Squibb to Take Part in the 7th Annual Truist Life Sciences Summit Business Wire
06:06AM	5 Surefire Dividend Stocks You Can Buy Right Now Motley Fool
Apr-27-21 06:06PM	Top Pharma Giants Expected to Be Most Active in M&A GuruFocus.com
11:00AM	SoftBank Leads $525 Million Fund Raise for U.K. Pharma Startup Bloomberg
10:29AM	INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Bristol-Myers Squibb Companys Directors and Officers for Breach of Fiduciary Duties BMY Business Wire
Apr-26-21 07:29PM	Eli Lilly Rated Tops in Innovation, Bristol-Myers Leader in Invention GuruFocus.com
Apr-24-21 07:18AM	Why Berkshire Hathaway's health care project Haven failed Yahoo Finance
Apr-23-21 02:35PM	Roche, AbbVie, Bristol-Myers Are Latest To Win European Medicines Agency's CHMP Positive Opinion Benzinga
02:29PM	What's in the Cards for Bristol-Myers (BMY) Q1 Earnings? Zacks
02:23PM	Bristol Myers' Psoriasis Med Deucravacitinib Superior To Amgen's Otezla, New Data Shows Benzinga
10:00AM	Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast) Business Wire
06:51AM	Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission Business Wire
06:45AM	Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma Business Wire
Apr-22-21 12:33PM	Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth Zacks
11:30AM	Is Bristol Myers Squibb (BMY) Stock Outpacing Its Medical Peers This Year? Zacks
08:12AM	Why Bristol Myers Squibb Deserves a Place in Your Portfolio Motley Fool
08:02AM	Bristol Myers To Build First Cell Therapy Factory In Europe Benzinga
Apr-21-21 10:11AM	12 Best Value Dividend Stocks to Buy Now According to Warren Buffett Insider Monkey
09:09AM	Were Hedge Funds Right About Piling Into Bristol Myers Squibb Company (BMY)? Insider Monkey
Apr-19-21 05:50PM	Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know Zacks
01:06PM	Bristol Myers (BMY) Opdivo Gets FDA Nod for Gastric Cancer Zacks
10:13AM	Bristol-Myers Squibbs Opdivo Receives US FDA Approval For Gastric Cancer Treatment SmarterAnalyst
06:19AM	Is Bristol-Myers Squibb Finally Ready for a Breakout? TheStreet.com
Apr-16-21 01:10PM	U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma.... Business Wire
11:48AM	Latest Upgrades and Downgrades: Bristol-Myers Squibb, Splunk, Tesla TheStreet.com
10:40AM	Bristol Myers Gastric-Cancer Treatment Cleared by FDA TheStreet.com
05:51AM	The Smartest Stocks to Buy With $200 Right Now Motley Fool
Apr-15-21 08:59AM	Bristol Myers' (BMY) Opdivo Combo Gets EU Nod for First-Line RCC Zacks
07:49AM	The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split Benzinga
Apr-14-21 04:16PM	Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma Business Wire
Apr-13-21 12:03PM	Why This Bristol-Myers Squibb Stock Analyst Is Turning Bullish On The Pharma Company's Pipeline Benzinga
05:00AM	Bristol-Myers Upgraded to Buy at Truist on Pipeline Strength TheStreet.com
Apr-10-21 08:30AM	Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial Business Wire
Apr-09-21 04:20PM	Bristol Myers' (BMY) Opdivo Combo Positive in ESCC Study Zacks
Apr-08-21 07:35PM	CORRECTING and REPLACING Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal... Business Wire
08:02AM	Bristol-Myers' Opdivo-Chemo Combo Associated With Overall Survival Benefit In Esophageal Cancer Benzinga
Apr-07-21 07:04AM	PsiOxus Therapeutics-Bristol Myers Expand Immuno-Oncology Collaboration Benzinga
Apr-06-21 05:50PM	Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know Zacks
04:08PM	Top Stock Reports for Alphabet, Visa & PayPal Zacks
12:45PM	3 Reasons Why Bristol Myers (BMY) Is a Great Growth Stock Zacks
11:30AM	Is Bristol Myers Squibb (BMY) Outperforming Other Medical Stocks This Year? Zacks
Apr-01-21 02:44PM	Bristol Myers In Over $1B Tax Brawl After Accidental Disclosure Of Offshore Patents Setup: NYT Benzinga
Mar-30-21 01:19PM	bluebird (BLUE), Bristol Myers CAR T Cell Therapy Gets FDA Nod Zacks
08:05AM	Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma PR Newswire
06:59AM	Bristol Myers Squibb to Host Virtual Investor Event to Discuss AAD VMX Highlights Business Wire
Mar-29-21 05:50PM	Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know Zacks
09:00AM	Bluebird Shares Jump as FDA Approves Cancer Therapy Barrons.com
08:48AM	Bristol Myers And bluebird bios CAR-T Cell Therapy For Multiple Myeloma Gains FDA Approval SmarterAnalyst
07:04AM	Bluebird Shares Jump On FDA Nod For Myeloma Therapy Investing.com
06:59AM	European Medicines Agency Validates Bristol Myers Squibbs Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma Business Wire
Mar-27-21 12:47AM	U.S. FDA approves Bristol-Myers Squibb's multiple myeloma therapy Reuters
Mar-26-21 10:59PM	U.S. Food and Drug Administration Approves Bristol Myers Squibbs and bluebird bios Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma Business Wire
12:00PM	Bristol-Myers (BMY) Announces Results From Opdivo Combo Study Zacks
01:30AM	Why It Might Not Make Sense To Buy Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming Dividend Simply Wall St.
Mar-25-21 06:59AM	Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival Business Wire
Mar-24-21 03:39PM	Five Prime's Revival a Lesson for Biotech Investors GuruFocus.com
Mar-23-21 03:15PM	Regenerative Medicine Attracted Record $20 Billion in Funding in 2020 GuruFocus.com
12:41PM	3 Undervalued Pharma Stocks for Sleep-Well-at-Night Income GuruFocus.com
Mar-22-21 05:50PM	Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know Zacks
09:42AM	FDA Accepts New Drug Application For Bristol Myers Squibbs Mavacamten SmarterAnalyst
08:21AM	Bristol Myers' (BMY) NDA for Mavacamten Accepted by FDA Zacks
Mar-19-21 07:03AM	3 Great Income Stocks to Buy Right Now Motley Fool
06:59AM	U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibbs Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) Business Wire
Mar-18-21 05:51AM	4 Value Stocks Billionaires Can't Stop Buying Motley Fool
Mar-17-21 08:22AM	The FTC Is Taking a More Aggressive Approach Toward Pharmaceutical M&A. What It Means for the Industry. Barrons.com

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; and Huyabio. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schmukler Louis S	EVP,Pres.,Glob.Prod. & Supply	May 10	Sale	65.25	15,000	978,750	31,956	May 11 04:39 PM
Eid Joseph	SVP,Head Glob. Medical Affairs	May 10	Sale	65.00	1,118	72,670	8,069	May 11 04:39 PM
VESSEY RUPERT	EVP, Research & Early Dev.	May 08	Option Exercise	0.00	17,245	0	62,384	May 11 04:38 PM
VESSEY RUPERT	EVP, Research & Early Dev.	May 05	Sale	64.29	30,546	1,963,802	45,139	May 07 04:56 PM
Dubow Adam	SVP,ChiefCompliance&EthicsOff.	May 05	Sale	64.21	3,119	200,271	16,243	May 07 04:57 PM
Mily Elizabeth	EVP, Strategy & BD	Apr 01	Option Exercise	0.00	6,346	0	5,380	Apr 02 01:14 PM
Caforio Giovanni	Chairman and CEO	Mar 22	Sale	62.20	25,000	1,555,000	528,980	Mar 24 04:41 PM
Dubow Adam	SVP,ChiefCompliance&EthicsOff.	Mar 10	Option Exercise	0.00	5,404	0	19,811	Mar 12 06:59 PM
BOERNER CHRISTOPHER S.	EVP, Chief Commercial Officer	Mar 10	Option Exercise	0.00	25,215	0	41,325	Mar 12 06:59 PM
Caforio Giovanni	Chairman and CEO	Mar 10	Option Exercise	0.00	200,709	0	603,187	Mar 12 06:59 PM
Eid Joseph	SVP,Head Glob. Medical Affairs	Mar 10	Option Exercise	0.00	6,134	0	9,862	Mar 12 06:58 PM
Elkins David V	EVP, Chief Financial Officer	Mar 10	Option Exercise	0.00	8,025	0	91,211	Mar 12 06:57 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Mar 10	Option Exercise	0.00	4,189	0	9,082	Mar 12 06:56 PM
LEUNG SANDRA	EVP, General Counsel	Mar 10	Option Exercise	0.00	50,373	0	383,564	Mar 12 06:52 PM
Santiago Karen Murphy	SVP & Controller	Mar 10	Option Exercise	0.00	7,483	0	14,717	Mar 12 06:50 PM
Powell Ann	EVP, Chief Human Resources	Mar 10	Option Exercise	0.00	29,835	0	76,125	Mar 12 06:51 PM
von Autenried Paul	EVP, Chief Information Officer	Mar 10	Option Exercise	0.00	20,302	0	143,800	Mar 12 06:50 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Mar 10	Option Exercise	0.00	7,423	0	79,051	Mar 12 06:50 PM
Schmukler Louis S	EVP,Pres.,Glob.Prod. & Supply	Mar 10	Option Exercise	0.00	31,575	0	53,018	Mar 12 06:50 PM
Elkins David V	EVP, Chief Financial Officer	Mar 01	Option Exercise	0.00	24,579	0	91,759	Mar 03 05:27 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Mar 01	Option Exercise	0.00	23,349	0	80,572	Mar 03 05:26 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Feb 04	Option Exercise	0.00	3,592	0	58,409	Feb 08 07:28 PM
Elkins David V	EVP, Chief Financial Officer	Dec 31	Option Exercise	0.00	20,624	0	79,111	Jan 05 08:13 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Dec 31	Option Exercise	0.00	25,866	0	68,074	Jan 05 08:14 PM
AHMED NADIM	EVP and President, Hematology	Dec 31	Option Exercise	0.00	14,946	0	46,549	Jan 05 08:13 PM
Elkins David V	EVP, Chief Financial Officer	Dec 02	Option Exercise	0.00	8,792	0	63,574	Dec 03 08:24 PM
AHMED NADIM	EVP and President, Hematology	Dec 02	Option Exercise	0.00	6,594	0	34,983	Dec 03 08:24 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Dec 02	Option Exercise	0.00	8,792	0	46,714	Dec 03 08:24 PM
BOERNER CHRISTOPHER S.	EVP, Chief Commercial Officer	Dec 02	Option Exercise	0.00	2,637	0	23,670	Dec 03 08:23 PM
Eid Joseph	SVP,Head Glob. Medical Affairs	Dec 01	Option Exercise	0.00	2,825	0	5,359	Dec 03 05:15 PM
von Autenried Paul	EVP, Chief Information Officer	Nov 25	Sale	63.50	3	190	126,698	Nov 30 05:52 PM
von Autenried Paul	EVP, Chief Information Officer	Nov 24	Sale	62.75	20,000	1,255,000	126,701	Nov 25 04:31 PM
Dubow Adam	SVP,ChiefCompliance&EthicsOff.	Nov 24	Sale	63.39	900	57,051	15,186	Nov 25 04:32 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Nov 23	Sale	61.34	13,421	823,244	37,922	Nov 25 04:32 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Nov 19	Option Exercise	49.28	52,213	2,572,887	98,355	Nov 23 05:40 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Nov 19	Sale	61.30	57,591	3,530,269	46,142	Nov 23 05:40 PM
AHMED NADIM	EVP and President, Hematology	Oct 30	Option Exercise	0.00	4,650	0	30,680	Nov 03 04:28 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Oct 30	Option Exercise	0.00	5,804	0	59,580	Nov 03 04:27 PM
Santiago Karen Murphy	SVP & Controller	Sep 01	Option Exercise	0.00	642	0	8,390	Sep 02 04:33 PM
Caforio Giovanni	Chairman and CEO	Aug 31	Sale	62.70	39,840	2,497,968	445,584	Sep 02 04:34 PM
Eid Joseph	SVP,Head Glob. Medical Affairs	Aug 17	Sale	64.00	5,327	340,928	2,534	Aug 19 06:15 PM
LEUNG SANDRA	EVP, General Counsel	Aug 13	Sale	63.24	141,420	8,943,401	432,744	Aug 17 04:55 PM
Elkins David V	EVP, Chief Financial Officer	Aug 01	Option Exercise	0.00	46,402	0	80,698	Aug 04 04:43 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Jul 01	Option Exercise	0.00	9,356	0	9,356	Jul 02 04:56 PM
Santiago Karen Murphy	SVP & Controller	Jul 01	Option Exercise	0.00	1,069	0	8,115	Jul 02 04:54 PM
Paliwal Dinesh C	Director	Jun 15	Buy	54.50	9,174	499,983	22,109	Jun 16 05:15 PM
BONNEY MICHAEL W	Director	Jun 14	Option Exercise	0.00	558	0	8,650	Jun 16 05:16 PM
Haller Julia A	Director	Jun 14	Option Exercise	0.00	558	0	6,819	Jun 16 05:15 PM
Haller Julia A	Director	Jun 13	Option Exercise	0.00	903	0	6,261	Jun 16 05:15 PM
BONNEY MICHAEL W	Director	Jun 13	Option Exercise	0.00	903	0	8,092	Jun 16 05:16 PM
Haller Julia A	Director	Jun 03	Option Exercise	0.00	2,949	0	5,358	Jun 05 04:39 PM
BONNEY MICHAEL W	Director	Jun 03	Option Exercise	0.00	2,949	0	7,189	Jun 05 04:40 PM
Eid Joseph	SVP,Head Glob. Medical Affairs	Jun 03	Option Exercise	0.00	2,154	0	8,599	Jun 09 07:15 PM
Dubow Adam	SVP,ChiefCompliance&EthicsOff.	May 22	Sale	61.01	3,200	195,232	16,086	May 26 05:17 PM
Schmukler Louis S	EVP,Pres.,Glob.Prod. & Supply	May 19	Sale	62.68	25,000	1,567,000	26,777	May 21 05:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience